CoChat

Human glycogenins maintain glucose homeostasis by regulating glycogen metabolism

Open access
Weng, Tzu-Han, Pien, Yu-Chung, Chen, Ching-Jou, Chen, Po-Pang, Tseng, Yu-Ting, Chen, Ying-Chen, Hsiao, Wen-Po, Lee, Ying-Ting, Chen, Yi-An, Chen, Yao-Chi, Lim, Carmay, Hsu, Tzu-Han, Lin, Sung-Jan, Yen, Hsin-Yung, Hsia, Kuo-Chiang, Tsai, Su-Yi · 2025 · Nature Communications

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Proper regulation of glycogen metabolism is fundamental to cellular energy homeostasis, and its disruption is associated with various metabolic disorders, including glycogen storage diseases (GSDs) and potentially diabetes. Despite glycogen’s role as an essential energy reservoir, the mechanisms governing its synthesis and structural diversity across tissues remain unclear. Here, we uncover the distinct physiological roles of the human glycogenins GYG1 and GYG2 in glycogen synthesis. Through cellular models, structural biology, and biochemical analyses, we demonstrate that, unlike GYG1, GYG2 exhibits minimal autoglycosylation activity and acts as a suppressor of glycogen formation. Together, these two glycogenins coordinate glycogen synthase activity and influence glycogen assembly in a cell-type-dependent manner. Importantly, these glycogenins modulate glucose metabolic pathways, thereby ensuring cellular glucose homeostasis. These findings address longstanding questions in glycogen metabolism and establish both GYG1 and GYG2 as critical regulators of glycogen synthesis and breakdown in human, providing insights with potential therapeutic implications for treating GSDs and metabolic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-61862-3

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Glycogen synthesis is reduced in GYG1 knockout hESCs. a Domain organization of human GYG1 and GYG2 (numbers represent residue positions in the protein sequence). Auto-glycosylation sites (GYG1: Y195; GYG2: Y228) are indicated. GSD denotes the glycogen synthase binding domain. b Protein levels of GYG1 and GYG2 in hESCs, as detected by Western blot. β-Actin served as the loading control. c, d Representative Periodic acid-Sciff (PAS) staining images of GYG1 knockout (KO) (c) and GYG2 KO (d) hESCs. The wild type (WT) and two independent cell clones of each knockout line were examined. Scale bars: 200 μm. e Western blot analysis of GYG1 and GYG2 protein levels in GYG1 KO and GYG2 KO hESCs. β-Actin served as the loading control. f Protein levels of GYG1 and GYG2 in WT, GYG1 KO, and double knockout (DKO) hESCs, as detected by Western blot. α-Tubulin served as the loading control. g Representative images of PAS (left panels) and immunofluorescence staining using glycogen antibody (middle panels) in the indicated cell lines, with overlay shown in the right panels (Merge). Two independent cell clones of the DKO line were examined. Glycogen is shown in green. Scale bars: 100 μm. h Bar graph of glycogen content in indicated cells. Glycogen contents were measured using a glycogen colorimetric kit. Data are mean ± standard deviation (SD) from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: ***P < 0.001. † Although the theoretical molecular weight of GYG2 is ~55 kDa (UniProt ID: O15488-1), the protein consistently migrates at ~66 kDa on SDS-PAGE, including when purified from insect cells (see Fig. 2i).
Fig. 1 Glycogen synthesis is reduced in GYG1 knockout hESCs. a Domain organization of human GYG1 and GYG2 (numbers represent residue positions in the protein sequence). Auto-glycosylation sites (GYG1: Y195; GYG2: Y228) are indicated. GSD denotes the glycogen synthase binding domain. b Protein levels of GYG1 and GYG2 in hESCs, as detected by Western blot. β-Actin served as the loading control. c, d Representative Periodic acid-Sciff (PAS) staining images of GYG1 knockout (KO) (c) and GYG2 KO (d) hESCs. The wild type (WT) and two independent cell clones of each knockout line were examined. Scale bars: 200 μm. e Western blot analysis of GYG1 and GYG2 protein levels in GYG1 KO and GYG2 KO hESCs. β-Actin served as the loading control. f Protein levels of GYG1 and GYG2 in WT, GYG1 KO, and double knockout (DKO) hESCs, as detected by Western blot. α-Tubulin served as the loading control. g Representative images of PAS (left panels) and immunofluorescence staining using glycogen antibody (middle panels) in the indicated cell lines, with overlay shown in the right panels (Merge). Two independent cell clones of the DKO line were examined. Glycogen is shown in green. Scale bars: 100 μm. h Bar graph of glycogen content in indicated cells. Glycogen contents were measured using a glycogen colorimetric kit. Data are mean ± standard deviation (SD) from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: ***P < 0.001. † Although the theoretical molecular weight of GYG2 is ~55 kDa (UniProt ID: O15488-1), the protein consistently migrates at ~66 kDa on SDS-PAGE, including when purified from insect cells (see Fig. 2i).CC BY · PubMed Central
Fig. 2 GYG2 negatively regulates glycogen synthesis. a Western blot of ectopic GYG2-FLAG expression in WT and DKO hESCs using anti-FLAG (n = 3). b PAS staining of WT, WTOE:GYG2, and DKOOE:GYG2 hESCs. Scale bars: 200 μm. (n = 3). c Glycogen quantification using colorimetric assay in indicated cell lines. Data are mean±SD (n = 3). One-way ANOVA (Tukey’s test); ***P < 0.001. d Western blot of pGS and GS in the indicated cell lines. e Bar graphs showing pGS and the ratio of pGS to GS. Data are mean ± SD (n = 5). One-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01, and ***P < 0.001. f Domain organization of GYG2 with sgRNA sites. PAS staining of WT, GYG1 KO and GYG1 KOKO:GSD2 hESCs (n = 3). Scale bars: 200 μm. g Western blot of pGS and GS (left) and quantification of pGS/GS (right). β-Actin was used as loading control. Data are mean±SD (n = 3). One-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01. h–j Size exclusion chromatography (Superose 6) elution profiles for GS•GYG1 (WT) (h), GS•GYG1 (Y195F) (i), and GS•GYG2 (j). Void volumes (Vo) are indicated. SDS-PAGE with Coomassie staining of peak fractions (bottom). n = 3. k SDS–PAGE and Western blot of WT/mutant GS•GYG1 complexes using anti-GYG1. l Western blot of GS•GYG2 and GYG2 alone using anti-GYG2. m GS activity of GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 with or without 2 mM G6P and 30 units lambda phosphatase (λPP). Asterisks * represents statistical comparisons relative to controls of each complex with or without G6P or λPP. # represents statistical comparison of GS•GYG1 (Y195F) and GS•GYG2 with the GS•GYG1 control. † represents statistical comparison of GS•GYG1 (Y195F) with GS•GYG2 under G6P or λPP treatment. Data are mean ± SD (n = 3). Two-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01, ***P < 0.001, # <0.05, ## <0.01, ### <0.001, †P < 0.05, ††P < 0.01, †††P < 0.001. n Native MS of GS•GYG2 and GS•GYG1 (Y195F) with G6P. Mass spectra show apo and G6P-bound states with binding stoichiometry. o, GS•GYG1 with increasing GYG2 before activity assay. Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s test); *P < 0.05, ***P < 0.001.
Fig. 2 GYG2 negatively regulates glycogen synthesis. a Western blot of ectopic GYG2-FLAG expression in WT and DKO hESCs using anti-FLAG (n = 3). b PAS staining of WT, WTOE:GYG2, and DKOOE:GYG2 hESCs. Scale bars: 200 μm. (n = 3). c Glycogen quantification using colorimetric assay in indicated cell lines. Data are mean±SD (n = 3). One-way ANOVA (Tukey’s test); ***P < 0.001. d Western blot of pGS and GS in the indicated cell lines. e Bar graphs showing pGS and the ratio of pGS to GS. Data are mean ± SD (n = 5). One-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01, and ***P < 0.001. f Domain organization of GYG2 with sgRNA sites. PAS staining of WT, GYG1 KO and GYG1 KOKO:GSD2 hESCs (n = 3). Scale bars: 200 μm. g Western blot of pGS and GS (left) and quantification of pGS/GS (right). β-Actin was used as loading control. Data are mean±SD (n = 3). One-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01. h–j Size exclusion chromatography (Superose 6) elution profiles for GS•GYG1 (WT) (h), GS•GYG1 (Y195F) (i), and GS•GYG2 (j). Void volumes (Vo) are indicated. SDS-PAGE with Coomassie staining of peak fractions (bottom). n = 3. k SDS–PAGE and Western blot of WT/mutant GS•GYG1 complexes using anti-GYG1. l Western blot of GS•GYG2 and GYG2 alone using anti-GYG2. m GS activity of GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 with or without 2 mM G6P and 30 units lambda phosphatase (λPP). Asterisks * represents statistical comparisons relative to controls of each complex with or without G6P or λPP. # represents statistical comparison of GS•GYG1 (Y195F) and GS•GYG2 with the GS•GYG1 control. † represents statistical comparison of GS•GYG1 (Y195F) with GS•GYG2 under G6P or λPP treatment. Data are mean ± SD (n = 3). Two-way ANOVA (Tukey’s test); *P < 0.05, **P < 0.01, ***P < 0.001, # <0.05, ## <0.01, ### <0.001, †P < 0.05, ††P < 0.01, †††P < 0.001. n Native MS of GS•GYG2 and GS•GYG1 (Y195F) with G6P. Mass spectra show apo and G6P-bound states with binding stoichiometry. o, GS•GYG1 with increasing GYG2 before activity assay. Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s test); *P < 0.05, ***P < 0.001.CC BY · PubMed Central
Fig. 3 GYG autoglycosylation is critical for GS activity. a Representative PAS staining image of the GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 complexes. b Quantification of the band intensity in (a). Data are mean ± SD from four independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, ***P < 0.001. c GS activity of the GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 complexes. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, ***P < 0.001. d Domain structure of human GYG1, GYG2 and chimeric GYG1. e The GS•chimeric GYG1 complex purified by SEC (Superose 6) was analyzed by SDS-PAGE and stained with Coomassie blue. The data represent three independent experiments. f WT and GS•chimeric GYG1 complexes were analyzed by SDS–PAGE followed by Western blotting using anti-GYG1 antibody. The data represent three independent experiments. g Representative PAS staining image of the GS•GYG1, GS•GYG2, and GS•chimeric GYG1 complexes. h GS activity of the GS•GYG1, GS•GYG2, and GS•chimeric GYG1 complexes under G6P or λPP treatment. Data are mean ± SD from three independent experiments. Two-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, **P < 0.01, ***P < 0.001, # <0.05, ## <0.01, ### <0.001, †P < 0.05, ††P < 0.01, †††P < 0.001. Asterisks * represent statistical comparison relative to control of each complex plus G6P or λPP treatment. # represents statistical comparison of the GS•GYG2 and GS•chimeric GYG1 complexes with GS•GYG1 basal activity. † represents statistical comparison of GS•chimeric GYG1 with GS•GYG2 under G6P or λPP treatment. i Ectopic expression of FLAG-tagged GYG1, GYG2, and chimeric GYG1 in our DKO hESC lines. Protein levels of GYG1, GYG2, and chimeric GYG1-FLAG in DKO hESCs were analyzed by Western blot using anti-FLAG antibody. β-Actin served as the loading control. j Bar graph showing glycogen content in DKO hESC lines ectopically expressing GYG1, GYG2, or chimeric GYG1. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: **P < 0.01.
Fig. 3 GYG autoglycosylation is critical for GS activity. a Representative PAS staining image of the GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 complexes. b Quantification of the band intensity in (a). Data are mean ± SD from four independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, ***P < 0.001. c GS activity of the GS•GYG1, GS•GYG1 (Y195F), and GS•GYG2 complexes. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, ***P < 0.001. d Domain structure of human GYG1, GYG2 and chimeric GYG1. e The GS•chimeric GYG1 complex purified by SEC (Superose 6) was analyzed by SDS-PAGE and stained with Coomassie blue. The data represent three independent experiments. f WT and GS•chimeric GYG1 complexes were analyzed by SDS–PAGE followed by Western blotting using anti-GYG1 antibody. The data represent three independent experiments. g Representative PAS staining image of the GS•GYG1, GS•GYG2, and GS•chimeric GYG1 complexes. h GS activity of the GS•GYG1, GS•GYG2, and GS•chimeric GYG1 complexes under G6P or λPP treatment. Data are mean ± SD from three independent experiments. Two-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: *P < 0.05, **P < 0.01, ***P < 0.001, # <0.05, ## <0.01, ### <0.001, †P < 0.05, ††P < 0.01, †††P < 0.001. Asterisks * represent statistical comparison relative to control of each complex plus G6P or λPP treatment. # represents statistical comparison of the GS•GYG2 and GS•chimeric GYG1 complexes with GS•GYG1 basal activity. † represents statistical comparison of GS•chimeric GYG1 with GS•GYG2 under G6P or λPP treatment. i Ectopic expression of FLAG-tagged GYG1, GYG2, and chimeric GYG1 in our DKO hESC lines. Protein levels of GYG1, GYG2, and chimeric GYG1-FLAG in DKO hESCs were analyzed by Western blot using anti-FLAG antibody. β-Actin served as the loading control. j Bar graph showing glycogen content in DKO hESC lines ectopically expressing GYG1, GYG2, or chimeric GYG1. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance is indicated: **P < 0.01.CC BY · PubMed Central
Fig. 4 Structural characterization of the GS•GYG2 complex. a Cryo-EM map of the heterotetrameric GS•GYG2 complex at 2.84 Å resolution. GS and the C-terminal domain of GYG2 (GYG2-CTD) subunits are colored separately. b–c, Structural superimposition of the GS•GYG2 complex with GS•GYG1 complex in the inhibited (b) or active (c) state. GS•GYG1 complexes are colored gray, and the color code of the GS•GYG2 complexes is as shown in (a). R.M.S.D. values are indicated. A 90o-rotated view is shown in the bottom panel. The PDB codes for GS•GYG1 complex in the inhibited and active states are 7Q0B and 7Q12, respectively. d AlphaFold3-predicted dimeric catalytic Rossmann fold domain of GYG1 (red) and GYG2 (green) across different species are superimposed, with R.M.S.D. values and manganese (Mn) indicated. The lid segment, the acceptor arm, and the C loop are highlighted. e Cartoon representation of the crystal structure of the GYG1 catalytic domain. The autoglycosylation site (Y195) and Y197 that facilitate homodimeric interaction through contacts with D160 and W128 in an adjacent molecule are depicted. f Superimposition of AlphaFold3-predicted monomeric catalytic Rossmann fold domain of human GYG1 (red) and GYG2 (green) with the C loop region is emphasized. g A zoomed-in view of the C loop region of human GYG1 (red) and GYG2 (green) highlighted by the black dashed box in f is shown. Key residues Y195 and P238 in GYG1 and their corresponding residues in GYG2 (Y228 and S271) are shown.
Fig. 4 Structural characterization of the GS•GYG2 complex. a Cryo-EM map of the heterotetrameric GS•GYG2 complex at 2.84 Å resolution. GS and the C-terminal domain of GYG2 (GYG2-CTD) subunits are colored separately. b–c, Structural superimposition of the GS•GYG2 complex with GS•GYG1 complex in the inhibited (b) or active (c) state. GS•GYG1 complexes are colored gray, and the color code of the GS•GYG2 complexes is as shown in (a). R.M.S.D. values are indicated. A 90o-rotated view is shown in the bottom panel. The PDB codes for GS•GYG1 complex in the inhibited and active states are 7Q0B and 7Q12, respectively. d AlphaFold3-predicted dimeric catalytic Rossmann fold domain of GYG1 (red) and GYG2 (green) across different species are superimposed, with R.M.S.D. values and manganese (Mn) indicated. The lid segment, the acceptor arm, and the C loop are highlighted. e Cartoon representation of the crystal structure of the GYG1 catalytic domain. The autoglycosylation site (Y195) and Y197 that facilitate homodimeric interaction through contacts with D160 and W128 in an adjacent molecule are depicted. f Superimposition of AlphaFold3-predicted monomeric catalytic Rossmann fold domain of human GYG1 (red) and GYG2 (green) with the C loop region is emphasized. g A zoomed-in view of the C loop region of human GYG1 (red) and GYG2 (green) highlighted by the black dashed box in f is shown. Key residues Y195 and P238 in GYG1 and their corresponding residues in GYG2 (Y228 and S271) are shown.CC BY · PubMed Central
Fig. 5 Metabolic reprogramming in GYG1 and GYG2 KO cells reveals distinct energy pathways and dynamic regulation of their interactions with GS under metabolic change. a, b Western blot analysis of WT, GYG1 KO, and GYG2 KO hESCs following metabolic changes. For (a), hESCs were starved and then treated with 50 mM glucose; for (b), cells were treated with 10 μM forskolin in starvation medium. Cell lysates were α-amylase–treated. β-Actin served as a loading control. Quantification is shown below each blot. Data are mean ± SD (n = 3) One-way ANOVA (Tukey’s multiple comparison test); Statistical significance was compared to the 0-hr time-point: *P < 0.05, **P < 0.01, and ***P < 0.001. c Co-IP followed by Western blot analysis of pGS (inactive) and GS (active) from DKOOE:GYG1-FLAG, DKOOE:GYG2-FLAG, and DKOOE:GYG1-FLAG&GYG2-HA, under sequential forskolin and glucose treatment. Cell lysates were pretreated with α-amylase before FLAG pulldown. Vinculin served as the loading control. (n = 3). d Seahorse analysis of oxygen consumption rate (OCR) to assess basal respiration, maximal respiration, and ATP production in WT, GYG1 KO, and GYG2 KO hESCs (n = 3). Data are mean ± SD. One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, and ***P < 0.001. e Seahorse analysis of extracellular acidification rate (ECAR) to assess glycolytic capacity, glycolysis, and glycolytic reserve. Data are mean ± SD (n = 4). One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, and ***P < 0.001. f, g Mass isotopomer distribution (MID) of [13C6] glucose-derived intermediates from glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle in WT, GYG1 KO, and GYG2 KO hESCs. hESCs were cultured for 2 hr in medium containing 17.5 mM [13C6] glucose (n = 3). f Heatmap of the total labeling percentage of metabolic flux in WT, GYG1 KO, and GYG2 KO hESCs. Scale bar represents relative fold change of overall metabolites. g Pie chart size represents overall metabolite abundance, and the total percentage of labeled metabolites is displayed in the table at bottom.
Fig. 5 Metabolic reprogramming in GYG1 and GYG2 KO cells reveals distinct energy pathways and dynamic regulation of their interactions with GS under metabolic change. a, b Western blot analysis of WT, GYG1 KO, and GYG2 KO hESCs following metabolic changes. For (a), hESCs were starved and then treated with 50 mM glucose; for (b), cells were treated with 10 μM forskolin in starvation medium. Cell lysates were α-amylase–treated. β-Actin served as a loading control. Quantification is shown below each blot. Data are mean ± SD (n = 3) One-way ANOVA (Tukey’s multiple comparison test); Statistical significance was compared to the 0-hr time-point: *P < 0.05, **P < 0.01, and ***P < 0.001. c Co-IP followed by Western blot analysis of pGS (inactive) and GS (active) from DKOOE:GYG1-FLAG, DKOOE:GYG2-FLAG, and DKOOE:GYG1-FLAG&GYG2-HA, under sequential forskolin and glucose treatment. Cell lysates were pretreated with α-amylase before FLAG pulldown. Vinculin served as the loading control. (n = 3). d Seahorse analysis of oxygen consumption rate (OCR) to assess basal respiration, maximal respiration, and ATP production in WT, GYG1 KO, and GYG2 KO hESCs (n = 3). Data are mean ± SD. One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, and ***P < 0.001. e Seahorse analysis of extracellular acidification rate (ECAR) to assess glycolytic capacity, glycolysis, and glycolytic reserve. Data are mean ± SD (n = 4). One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, and ***P < 0.001. f, g Mass isotopomer distribution (MID) of [13C6] glucose-derived intermediates from glycolysis, the pentose phosphate pathway (PPP), and the tricarboxylic acid (TCA) cycle in WT, GYG1 KO, and GYG2 KO hESCs. hESCs were cultured for 2 hr in medium containing 17.5 mM [13C6] glucose (n = 3). f Heatmap of the total labeling percentage of metabolic flux in WT, GYG1 KO, and GYG2 KO hESCs. Scale bar represents relative fold change of overall metabolites. g Pie chart size represents overall metabolite abundance, and the total percentage of labeled metabolites is displayed in the table at bottom.CC BY · PubMed Central
Fig. 6 Glycogen particle size is reduced in GYG2-free cell lines. a Representative transmission electron microscopy (TEM) images of glycogen particles isolated from the indicated cell lines. Low and high magnification images are shown in the upper and lower panels, respectively. Scale bars: 100 nm. b Plot of glycogen particle diameter in the indicated cell lines. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance: ***P < 0.001 (n = at least 300 glycogen particles in total for each cell line). c Percentages of α ( > 40 nm), β (10-40 nm), and small β ( < 10 nm) particles isolated from the indicated cell lines, represented by red, green, and blue bars, respectively. Data are mean ± SD from three independent experiments. * represents a statistical comparison of each small β particle with WT. # represents a statistical comparison of each β particle with WT. † represents a statistical comparison of each α particles with WT. Differences were assessed statistically using two-way ANOVA (Tukey’s multiple comparison test); ***P < 0.001, ###P < 0.001, †††P < 0.001 (n = at least 300 glycogen particles in total for each cell line). d Glycogen particles isolated from the indicated cell lines were analyzed by SEC-MALLs. UV absorbance is measured in arbitrary units (a.u.). Elution volumes of the particles are indicated. The average molecular mass (M.W.) for the particles is shown above the plots. e–g Representative transmission electron microscopy (TEM) images of glycogen particles isolated from DKO lines subjected to three different concentrations (weak, middle, and strong) of GYG1 (e) or GYG2 (g). f Representative TEM images of glycogen particles isolated from DKOOE:GYG1 hESCs subjected to three different concentrations (weak, middle, and strong) of GYG2. In e–g, cartoons illustrating the appearance of indicated glycogen particles are shown in the right side of indicated images; quantification analysis of particle sizes is presented in the panels at right (n = at least total 300 glycogen particles in each cell line). Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance: *P < 0.05, **P < 0.01, and ***P < 0.001. All scale bars represent 100 nm.
Fig. 6 Glycogen particle size is reduced in GYG2-free cell lines. a Representative transmission electron microscopy (TEM) images of glycogen particles isolated from the indicated cell lines. Low and high magnification images are shown in the upper and lower panels, respectively. Scale bars: 100 nm. b Plot of glycogen particle diameter in the indicated cell lines. Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance: ***P < 0.001 (n = at least 300 glycogen particles in total for each cell line). c Percentages of α ( > 40 nm), β (10-40 nm), and small β ( < 10 nm) particles isolated from the indicated cell lines, represented by red, green, and blue bars, respectively. Data are mean ± SD from three independent experiments. * represents a statistical comparison of each small β particle with WT. # represents a statistical comparison of each β particle with WT. † represents a statistical comparison of each α particles with WT. Differences were assessed statistically using two-way ANOVA (Tukey’s multiple comparison test); ***P < 0.001, ###P < 0.001, †††P < 0.001 (n = at least 300 glycogen particles in total for each cell line). d Glycogen particles isolated from the indicated cell lines were analyzed by SEC-MALLs. UV absorbance is measured in arbitrary units (a.u.). Elution volumes of the particles are indicated. The average molecular mass (M.W.) for the particles is shown above the plots. e–g Representative transmission electron microscopy (TEM) images of glycogen particles isolated from DKO lines subjected to three different concentrations (weak, middle, and strong) of GYG1 (e) or GYG2 (g). f Representative TEM images of glycogen particles isolated from DKOOE:GYG1 hESCs subjected to three different concentrations (weak, middle, and strong) of GYG2. In e–g, cartoons illustrating the appearance of indicated glycogen particles are shown in the right side of indicated images; quantification analysis of particle sizes is presented in the panels at right (n = at least total 300 glycogen particles in each cell line). Data are mean ± SD from three independent experiments. One-way ANOVA (Tukey’s multiple comparison test); Statistical significance: *P < 0.05, **P < 0.01, and ***P < 0.001. All scale bars represent 100 nm.CC BY · PubMed Central
Fig. 7 An appropriate glycogen particle size distribution requires proper amounts of both GYG1 and GYG2 in different cell lineages. a Western blots showing GYG1 and GYG2 levels from WT-derived hepatocytes, neurons, and skeletal muscles, with or without α-amylase treatment. Vinculin served as the loading control (n = 3). b TEM images of isolated glycogen particles. Scale bars: 100 nm. c Proportions of α (>40 nm) and β (10–40 nm) particles in the indicated cell types (n = 3). Data are mean ± SD (n = 3). †, and # represent statistical comparisons of α particles, and β particles in neurons, cardiomyocytes, and skeletal muscle relative to hepatocytes, respectively. Differences were assessed statistically using two-way ANOVA (Tukey’s multiple comparison test); ### P < 0.001, ††† P < 0.001. d Glycogen content in indicated cell types. Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, ***P < 0.001. e, f Western blot analysis of pGS, GYG1, and GYG2 protein levels in cell extracts isolated from the indicated cell line-derived hepatocytes (e) and cardiomyocytes (f). β-Actin and Vinculin served as the loading control. Quantification analysis of pGS and GYG2 protein levels is presented in the panels at right. Data are mean ± SD (n = 3). Differences were assessed statistically using one-way ANOVA (Tukey’s multiple comparison test). *P < 0.05, **<0.01. g TEM images and particle diameter quantification of glycogen in hepatocytes (n = 100–150 particles/cell line). Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s multiple comparison test); ***P < 0.001. Scale bars: 100 nm. h PAS staining of WT and GYG1 KO cardiomyocytes with or without α-amylase (n = 3). Scale bars: 200 μm. i TEM images of WT- and GYG1 KO-derived cardiomyocytes (upper) and glycogen particles (lower) (n = 3). Scale bars: 500 nm (upper) and 100 nm (lower). j TEM images of glycogen particles isolated from the indicated cell line-derived neuron cells (upper) and skeletal muscle (lower) (n = 3). Scale bars: 100 nm. k pGS and GYG2 levels in GYG1 KO cardiomyocytes treated with 0, 10, or 30 µM GW9662 (M6191, Sigma) for 24 h. Vinculin as control. Data are mean ± SD (n = 3). Differences were assessed statistically using one-way ANOVA (Tukey’s multiple comparison test). *P < 0.05. l PAS staining of GYG1 KO-derived cardiomyocytes ± GW9662 treatment (n = 3). Scale bars: 100 μm.
Fig. 7 An appropriate glycogen particle size distribution requires proper amounts of both GYG1 and GYG2 in different cell lineages. a Western blots showing GYG1 and GYG2 levels from WT-derived hepatocytes, neurons, and skeletal muscles, with or without α-amylase treatment. Vinculin served as the loading control (n = 3). b TEM images of isolated glycogen particles. Scale bars: 100 nm. c Proportions of α (>40 nm) and β (10–40 nm) particles in the indicated cell types (n = 3). Data are mean ± SD (n = 3). †, and # represent statistical comparisons of α particles, and β particles in neurons, cardiomyocytes, and skeletal muscle relative to hepatocytes, respectively. Differences were assessed statistically using two-way ANOVA (Tukey’s multiple comparison test); ### P < 0.001, ††† P < 0.001. d Glycogen content in indicated cell types. Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s multiple comparison test); *P < 0.05, **P < 0.01, ***P < 0.001. e, f Western blot analysis of pGS, GYG1, and GYG2 protein levels in cell extracts isolated from the indicated cell line-derived hepatocytes (e) and cardiomyocytes (f). β-Actin and Vinculin served as the loading control. Quantification analysis of pGS and GYG2 protein levels is presented in the panels at right. Data are mean ± SD (n = 3). Differences were assessed statistically using one-way ANOVA (Tukey’s multiple comparison test). *P < 0.05, **<0.01. g TEM images and particle diameter quantification of glycogen in hepatocytes (n = 100–150 particles/cell line). Data are mean ± SD (n = 3). One-way ANOVA (Tukey’s multiple comparison test); ***P < 0.001. Scale bars: 100 nm. h PAS staining of WT and GYG1 KO cardiomyocytes with or without α-amylase (n = 3). Scale bars: 200 μm. i TEM images of WT- and GYG1 KO-derived cardiomyocytes (upper) and glycogen particles (lower) (n = 3). Scale bars: 500 nm (upper) and 100 nm (lower). j TEM images of glycogen particles isolated from the indicated cell line-derived neuron cells (upper) and skeletal muscle (lower) (n = 3). Scale bars: 100 nm. k pGS and GYG2 levels in GYG1 KO cardiomyocytes treated with 0, 10, or 30 µM GW9662 (M6191, Sigma) for 24 h. Vinculin as control. Data are mean ± SD (n = 3). Differences were assessed statistically using one-way ANOVA (Tukey’s multiple comparison test). *P < 0.05. l PAS staining of GYG1 KO-derived cardiomyocytes ± GW9662 treatment (n = 3). Scale bars: 100 μm.CC BY · PubMed Central
Fig. 8 Physiological relevance of dynamic regulation of GYG1 and GYG2 and their interactions with GS in glycogen metabolism. GYG1 and GYG2 play distinct roles in glycogen metabolism. GYG1 functions as a glycogen primer through its autoglycosylation activity, promoting glycogen synthesis and the formation of glycogen β particles. GYG2, however, lacks autoglycosylation capability and cannot compensate for GYG1’s role. Instead, GYG2 binds to glycogen synthase (GS) and enhances its phosphorylation, leading to decreased GS activity and reduced glycogen synthesis. Notably, in addition to regulating glycogen synthesis, GYG2 expression also controls glycogen particle size, as the formation of glycogen α particles requires both GYG1 and GYG2. Thus, the dynamic expression of GYG1 and GYG2 under metabolic change is crucial for maintaining glycogen balance. In the absence of GYG1 or GYG2, the regulatory mechanisms for glycogen balance are disrupted, leading to metabolic reprogramming and altered glycogen content, which affects normal physiological function. This model highlights GYG2 as a negative regulator of glycogenesis by modulating GS activity and influencing glycogen particle morphology. Created with BioRender.com.
Fig. 8 Physiological relevance of dynamic regulation of GYG1 and GYG2 and their interactions with GS in glycogen metabolism. GYG1 and GYG2 play distinct roles in glycogen metabolism. GYG1 functions as a glycogen primer through its autoglycosylation activity, promoting glycogen synthesis and the formation of glycogen β particles. GYG2, however, lacks autoglycosylation capability and cannot compensate for GYG1’s role. Instead, GYG2 binds to glycogen synthase (GS) and enhances its phosphorylation, leading to decreased GS activity and reduced glycogen synthesis. Notably, in addition to regulating glycogen synthesis, GYG2 expression also controls glycogen particle size, as the formation of glycogen α particles requires both GYG1 and GYG2. Thus, the dynamic expression of GYG1 and GYG2 under metabolic change is crucial for maintaining glycogen balance. In the absence of GYG1 or GYG2, the regulatory mechanisms for glycogen balance are disrupted, leading to metabolic reprogramming and altered glycogen content, which affects normal physiological function. This model highlights GYG2 as a negative regulator of glycogenesis by modulating GS activity and influencing glycogen particle morphology. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 9

Metadata

Authors
Weng, T.-H., Pien, Y.-C., Chen, C.-J., Chen, P.-P., Tseng, Y.-T., Chen, Y.-C., Hsiao, W.-P., Lee, Y.-T., Chen, Y.-A., Chen, Y.-C., Lim, C., Hsu, T.-H., Lin, S.-J., Yen, H.-Y., Hsia, K.-C., & Tsai, S.-Y.
Affiliations
  • National Taiwan University (TW)
  • Institute of Molecular Biology, Academia Sinica (TW)
  • Institute of Biomedical Sciences, Academia Sinica (TW)
  • Institute of Biological Chemistry, Academia Sinica (TW)
Corresponding author
  • Hsia, Kuo-Chiang
  • Tsai, Su-Yi
Venue
Nature Communications
Published
2025-07-16
Volume
16
Issue
1
Pages
6556-6556
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4412479221
Cited by
9
References
40
Citations by year
2026: 8 · 2025: 1
FWCI
6.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Taiwan University (112L895405, 113L893105)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
glycogenin, glycogen synthesis, glycogenolysis, glycogen synthase, glucose homeostasis, glycogen storage disease, cell type-dependent regulation, glycogen metabolism
MeSH terms
Human Embryonic Stem Cells, Cell Line, Glucose, Glucosyltransferases, Glycogen, Glycoproteins, Glycosylation, Homeostasis, Humans, Models, Molecular, Particle Size, Phosphorylation, Protein Binding, Protein Structure, Tertiary, Protein Structure, Quaternary

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human glycogenins maintain glucose homeostasis by regulating glycogen metabolism. https://app.cochat.ai/papers/10.1038/s41467-025-61862-3
The paper
Weng, T.-H., Pien, Y.-C., Chen, C.-J., Chen, P.-P., Tseng, Y.-T., Chen, Y.-C., Hsiao, W.-P., Lee, Y.-T., Chen, Y.-A., Chen, Y.-C., Lim, C., Hsu, T.-H., Lin, S.-J., Yen, H.-Y., Hsia, K.-C., & Tsai, S.-Y. (2025). Human glycogenins maintain glucose homeostasis by regulating glycogen metabolism. Nature Communications. https://doi.org/10.1038/s41467-025-61862-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.